报价延迟最少15分钟:2026/10/01 14:52 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.085 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-25.89/-0.83
|
|
企业价值
8.04M
|
| 资产负债 |
|
每股账面净值
1.82
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
3.92M
|
|
每股收益
0.07
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases. |
